# US 11,110,185 B2 · Combination formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,110,185 B2
- Document ID: US11110185B2
- Status: Granted
- Kind: B2
- Application number: 15/768,831
- Filed: 2016-11-30
- Published: 2018-10-25
- Granted: 2021-09-07
- Earliest claimed: 2015-11-30
- Assignees: Ge Healthcare Limited
- Applicants: GE Healthcare AS
- Inventors: Andreas Richard Meijer; Mikkel Jacob Thaning; Paritosh Jayant Dhawale; Salvatore Desena; Paul Alexander Jones; Deirdre Cassidy; Concetta Valeria Gringeri
- Web page: https://patentgrep.com/patent/US11110185B2

## CPC

- A61K 49/105: {the metal complex being Gd-DTPA}
- A61K 49/101: {the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals}
- A61K 49/108: {the metal complex being Gd-DOTA}
- A61K 2123/00: Preparations for testing in vivo
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to in vivo imaging and in particular to magnetic resonance imaging (MRI). Provided by the present invention is a pharmaceutical formulation suitable for use in an MRI procedure and which offers advantages over known such formulations. A particular dose of the pharmaceutical formulation of the invention is also envisioned as well as the use of said dose in a method of in vivo imaging. This present invention provides for simultaneous administration of a liver specific agent and a second MR contrast agent that is capable of better/further enhancing the dynamic vascular phase in a patient. The method of the invention has the advantage of simplicity and patient comfort, compared to sequential injections. Furthermore, the method of the invention provides the advantage that it can enable a lower cumulative dose of contrast agents.

## Claims

### Claim 1

A pharmaceutical composition comprising:
(i) a first active pharmaceutical ingredient (API) having greater than 10% hepatocellular uptake and biliary excretion, wherein the first API is gadoexetate; and,
(ii) a second API that is a metal chelate comprising a chelant or a derivative thereof and a paramagnetic metal ion, said second API having renal excretion and a lower level of hepatocellular uptake and biliary excretion than the first API;
(iii) a biocompatible carrier comprising excess free chelant in a form suitable for mammalian administration;
wherein the ratio of said first API to said second API is from 1:10 to 4:1.

### Claim 2 (depends on 1)

The pharmaceutical composition as defined in claim 1 wherein said paramagnetic metal ion is a transition metal or a lanthanide.

### Claim 3 (depends on 2)

The pharmaceutical composition as defined in claim 2 wherein said paramagnetic metal ion is selected from the group comprising Eu, Gd, Dy, Ho, Cr, Mn and Fe.

### Claim 4 (depends on 3)

The pharmaceutical composition as defined in claim 3 wherein said paramagnetic metal ion is selected from the group comprising Gd, Mn, Fe and Cr.

### Claim 5 (depends on 4)

The pharmaceutical composition as defined in claim 4 wherein said paramagnetic metal ion is selected from the group comprising Gd(III) and Mn(II).

### Claim 6 (depends on 5)

The pharmaceutical composition as defined in claim 5 wherein said paramagnetic metal ion is Gd(III).

### Claim 7 (depends on 1)

The pharmaceutical composition as defined in claim 1 wherein said chelant or derivative thereof is selected from the group comprising:
diethylenetriaminepentaacetic acid (DTPA); 4-carboxy-5, 8, 11-tris(carboxymethyl)-1-phenyl-2oxa-5, 8, 11-triazatridecan-13-oic acid (BOPTA); 1, 4, 7, 10-tetraazacyclododecan-1, 4, 7-triactetic acid (DO3A),); 1, 4, 7, 10-tetraazacyclododecan-1, 4, 7, 10-tetraactetic acid (DOTA); ethylenediaminotetraacetic acid (EDTA); 10-(2-hydroxypropyl)-1, 4, 7, 10-tetraazacyclododecan-1, 4, 7-triacetic acid (HP-DO3A); 2-methyl-1, 4, 7, 10-tetraazacyclododecan-1, 4, 7, 10-tetraacetic acid (MCTA); tetra methyl-1, 4, 7, 10-tetraazacyclododecan-1, 4, 7, 10-tetraacetic acid (DOTMA); 3, 6, 9, 15-tetraazabicyclo[9.3.1]pentadeca-1(15), 11, 13-triene-3, 6, 9-triacetic acid (PCTA),); N, N′Bis(2-aminoethyl)-1,2-ethanediamine (TETA); 1,4,7,10-tetraazacyclotridecane-N,N′,N″,N′″-tetraacetic acid (TRITA),); 1,12-dicarbonyl, 15-(4-isothiocyanatobenzyl) 1, 4, 7, 10, 13-pentaazacyclohexadecane-N, N′, N″ triaceticacid (HETA); [(2S,5S,8S,11S)-4,7-bis-carboxymethyl-2,5,8,11-tetramethyl-1,4,7,10-tetraazacyclo-dodecan-1-yl]acetic acid, (M4DO3A); 1 1-O-Phosphonomethyl-1,4,7, 1-0-tetraazacyclododecane-1,4,7-triacetic acid (MPDO3A),); hydroxybenzyl-ethylenediamine-diacetic acid (HBED); and, N,N′-ethylenebis-[2-(o-hydroxyphenolic)glycine](EHPG); 2-[[2-[bis(carboxylatomethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate (EOB-DTPA); 10-[(1SR,2RS)-2,3-dihydroxy-1-hydroxymethylpropyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (BT-DO3A); 2-[bis[2-[carboxylatomethyl-[2-(methylamino)-2-oxoethyl]amino]ethyl]amino]acetate (DTPA-BMA); and, 2-[bis[2-[carboxylatomethyl-[2-(2-methoxyethylamino)-2-oxoethyl]amino]ethyl]amino]acetate (DTPA-BMEA); N-[2-[bis(carboxymethyl)amino]-3-(4-ethoxyphenyl)propyl]-N-[2-[bis(carboxymethyl)-amino]ethyl]-L-glycine (EOB-DTPA), N,N-bis[2-[bis(carboxymethyl)amino]-ethyl]-L-glutamic acid (DTPA-Glu), N,N-bis[2-[bis(carboxymethyl)amino]-ethyl]-L-lysine (DTPA-Lys), N,N-bis[2-[carboxymethyl[(methylcarbamoyl)methyl]amino]-ethyl] glycine (DTPA-BMA); 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid mono-(N-hydroxysuccinimidyl) ester (DOTA-NHS); [(2S,5S, 8S, 11S)-4,7,10-tris-carboxymethyl-2,5,8,11-tetramethyl-1,4,7,10-tetraazacyclododecan-1-yl]acetic acid (M4DOTA); (R)-2-[(2S,5S,8S,11S)-4,7,10-tris-((R)-1-carboxyethyl)-2,5,8,11-tetramethyl-1,4,7,10-tetraazacyclododecan-1-yl]propionic acid (M4DOTMA); PCTA12; cyclo-PCTA12; N, N′-Bis(2-aminoethyl)-1,2-ethanediamine-N-hydroxy-succinimide ester (TETA-NHS).

### Claim 8 (depends on 1)

A dose of a pharmaceutical composition to be administered to a subject wherein said pharmaceutical composition is as defined in claim 1 and wherein said dose comprises between 0.01-0.04 mmol per kilogram of said subject of said first API and between 0.01-0.1 mmol per kilogram of said subject of said second API with the proviso that the combined dose of said first API and second API does not exceed 0.125 mmol per kilogram of said subject.

### Claim 9 (depends on 8)

The dose as defined in claim 8 wherein the combined dose of said first API and second API is less than 0.125 mmol per kilogram of said subject.

### Claim 10 (depends on 8)

The dose as defined in claim 8 which comprises between 0.02-0.03 mmol per kilogram of said subject of said first API.

### Claim 11 (depends on 8)

The dose as defined in claim 8 which comprises between 0.025-0.1 mmol per kilogram of said subject of said second API wherein said second API has a relaxivity ≥3 mM−1 s−1 at field strengths of 1.5-3 T.

### Claim 12 (depends on 8)

The dose as defined in claim 8 which comprises between 0.02-0.09 mmol per kilogram of said subject of said second API wherein said second API has a relaxivity ≥5 mM−1 s−1 at field strengths of 1.5-3 T.

### Claim 13 (depends on 8)

The dose as defined in claim 8 which comprises between 0.02-0.07 mmol per kilogram of said subject of said second API wherein said second API has a relaxivity ≥7 mM−1 s−1 and field strengths of 1.5-3 T.

### Claim 14 (depends on 8)

The dose as defined in claim 8 which comprises between 0.01-0.06 mmol per kilogram of said subject of said second API wherein said second API has a relaxivity ≥9 mM−1 s−1 at field strengths of 1.5-3 T.

### Claim 15 (depends on 8)

The dose as defined in claim 8 which comprises 0.025 mmol per kilogram of said subject of said first API.

### Claim 16 (depends on 8)

The dose as defined in claim 8 which comprises 0.1 mmol per kilogram of said subject of said second API.

### Claim 17 (depends on 8)

The dose as defined in claim 8 which comprises 0.05 mmol per kilogram of said subject of said second API.

### Claim 18 (depends on 8)

The dose as defined in claim 8 wherein said subject is a living human or non-human animal body.

### Claim 19

A method comprising:
(a) administering a dose of a pharmaceutical composition to a subject wherein said dose comprises:
(i) a first active pharmaceutical ingredient (API) having hepatocellular uptake and biliary excretion, wherein the first API is gadoexetate; and,
(ii) a second API that is a metal chelate comprising a chelant or a derivative thereof and a paramagnetic metal ion, said second API having renal excretion and a lower level of hepatocellular uptake and biliary excretion than the first API;
(iii) a biocompatible carrier comprising excess free chelant in a form suitable for mammalian administration;
wherein the ratio of said first API to said second API is from 1:10 to 4:1,
(b) carrying out magnetic resonance imaging (MRI) on said subject following said administering step wherein magnetic resonance (MR) signals are detected from the subject or parts of the subject into which the dose has distributed; and
(c) generating MR images and/or MR spectra from the detected MR signals.

### Claim 20 (depends on 19)

The method as defined in claim 19, wherein said subject is a living human or nonhuman animal body.

### Claim 21 (depends on 19)

The method as defined in claim 19, wherein said composition is administered in an amount suitable to enhance the contrast in the method of MR imaging.

### Claim 22 (depends on 1)

The pharmaceutical composition of claim 1, wherein the proportion of hepatobiliary clearance of said first API is between 10-50%.

### Claim 23 (depends on 1)

The pharmaceutical composition of claim 1, wherein the proportion of hepatobiliary clearance of said first API is between 20-50%.

### Claim 24 (depends on 1)

The pharmaceutical composition of claim 1, wherein the proportion of hepatobiliary clearance of said first API is between 30-50%.

### Claim 25 (depends on 1)

The pharmaceutical composition of claim 1, wherein the proportion of hepatobiliary clearance of said first API is between 40-50%.

### Claim 26 (depends on 22)

The pharmaceutical composition of claim 22, wherein the proportion of hepatobiliary clearance of said second API is no more than 5%.

### Claim 27 (depends on 22)

The pharmaceutical composition of claim 22, wherein the proportion of hepatobiliary clearance of said second API is no more than 5%.

### Claim 28 (depends on 27)

The pharmaceutical composition of claim 27, wherein second API is selected from Gadoterate or Gadobutrol.